estimated glomerular filtration rate	0	1.0	2	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	
hepatic impairment diabetic ketoacidosis	0	1.0	2	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
plasma glucose control support	0	1.0	2	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
regulatory agency mhra guidance	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
single non-insulin blood glucose	0	1.0	2	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	
individualised care 1.1.1 adopt	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
body weight loss target	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
initial body weight loss	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
initial body weight loss target	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
drug treatment(s) on:the effectiveness	0	0.5774	2	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	
erratic blood glucose control	0	0.5774	2	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
offer group education programmes	0	0.5774	2	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	
active insulin dose titration	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
painful diabetic peripheral neuropathy	0	0.5	2	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	
support self-monitoring dose titration	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
telephone support self-monitoring dose	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
telephone support self-monitoring dose titration	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
first-line antihypertensive drug treatment	0	0.4295	6	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
contributory sympathetic nervous system	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
sympathetic nervous system damage	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
short-acting human insulin preparations	0	0.3334	2	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
blood pressure management 1.4.1	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
drug treatment1.6.19 offer standard-release	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
drug treatment1.6.19 offer standard-release metformin	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
initial drug treatment1.6.19 offer	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
initial drug treatment1.6.19 offer standard-release	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
management 1.4.1 measure blood	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
pressure management 1.4.1 measure	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
treatment1.6.19 offer standard-release metformin	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
insulin glargine if:the person	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
tight blood glucose control	0	0.3104	2	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
pre-mixed biphasic insulin preparation	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
erectile dysfunction1.7.13 offer men	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
